Coënon Loïs, Villalba Martin
Institute for Regenerative Medicine and Biotherapy (IRMB), Univ Montpellier, Institut national de la santé et de la recherche médicale (INSERM), Montpellier, France.
Institut du Cancer Avignon-Provence Sainte Catherine, Avignon, France.
Front Immunol. 2022 Jun 3;13:913215. doi: 10.3389/fimmu.2022.913215. eCollection 2022.
Antibody-dependent cell-mediated cytotoxicity (ADCC) is a potent cytotoxic mechanism that is mainly mediated in humans by natural killer (NK) cells. ADCC mediates the clinical benefit of several widely used cytolytic monoclonal antibodies (mAbs), and increasing its efficacy would improve cancer immunotherapy. CD16a is a receptor for the Fc portion of IgGs and is responsible to trigger NK cell-mediated ADCC. The knowledge of the mechanism of action of CD16a gave rise to several strategies to improve ADCC, by working on either the mAbs or the NK cell. In this review, we give an overview of CD16a biology and describe the latest strategies employed to improve antibody-dependent NK cell cytotoxicity.
抗体依赖的细胞介导的细胞毒性作用(ADCC)是一种强大的细胞毒性机制,在人类中主要由自然杀伤(NK)细胞介导。ADCC介导了几种广泛使用的溶细胞性单克隆抗体(mAb)的临床益处,提高其疗效将改善癌症免疫治疗。CD16a是IgG Fc部分的受体,负责触发NK细胞介导的ADCC。对CD16a作用机制的了解催生了几种通过作用于单克隆抗体或NK细胞来改善ADCC的策略。在本综述中,我们概述了CD16a的生物学特性,并描述了用于提高抗体依赖的NK细胞细胞毒性的最新策略。